Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines

Isabella Rimoldi, Valentina Coccè, Giorgio Facchetti, Giulio Alessandri, Anna Teresa Brini, Francesca Sisto, Eugenio Parati, Loredana Cavicchini, Giorgio Lucchini, Francesco Petrella, Emilio Ciusani, Augusto Pessina

Research output: Contribution to journalArticlepeer-review

Abstract

In this study, the in vitro stability of cisplatin (CisPt) and cationic platinum(II)-complex (caPt(II)-complex) and their in vitro activity (antiproliferative and anti-angiogenic properties) were investigated against three aggressive human tumor cell lines. caPt(II)-complex shown a high stability until 9 days of treatment and displayed a significant and higher activity than CisPt against both NCI-H28 mesothelioma (19.37 ± 9.57 μM versus 34.66 ± 7.65 μM for CisPt) and U87 MG glioblastoma (19.85 ± 0.97 μM versus 54.14 ± 3.19 for CisPt). Mesenchymal Stromal Cells (AT-MSCs) showed a significant different sensitivity (IC50 = 71.9 ± 15.1 μM for caPt(II)-complex and 8.7 ± 4.5 μM for CisPt) to the antiproliferative activity of caPt(II)-complex and CisPt. The ability of MSCs to uptake both the drugs in a similar amount of 2.49 pM /cell, suggested a possible development of new therapies based on cell mediated drug delivery.

Original languageEnglish
Pages (from-to)111-118
Number of pages8
JournalBiomedicine and Pharmacotherapy
Volume108
DOIs
Publication statusPublished - Dec 2018

Fingerprint

Dive into the research topics of 'Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines'. Together they form a unique fingerprint.

Cite this